Device Trial Radar · NCT03733210
Panitumumab-IRDye800 and 89Zr-Panitumumab in Identifying Metastatic Lymph Nodes in Patients With Squamous Cell Head and Neck Cancer
Last checked: Nov 19, 2026Latest source record: May 19, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
14
Actual
Start
Jan 7, 2019
Primary completion
Dec 11, 2020
Study completion Aug 9, 2021
Sponsor
- Lead sponsor
- Andrei IagaruAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institutes of Health (NIH); National Cancer Institute (NCI)
- First posted
- Nov 7, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study evaluates how well panitumumab-IRDye800 and 89Zr-panitumumab work in identifying cancer that has spread to the lymph nodes in patients with squamous cell head and neck cancer. Panitumumab-IRDye800 is a drug that contains a dye molecule that fluoresces during surgery to indicate cancerous tissue. 89Zr-panitumumab is a drug that contains a small amount of radiation, which makes it visible in positron emission tomography (PET) scans. PET scans make detailed, computerized pictures of areas inside the body where the drug is used. Giving panitumumab-IRDye800 and 89Zr-panitumumab to patients with head and neck cancer may help doctors find metastatic lymph nodes better than current methods \[positron emission tomography (PET); computed tomography (CT); magnetic imaging resonance (MRI), or combinations\].
Conditions
- Squamous Cell Carcinoma of the Head and Neck
- Carcinoma of the Head and Neck
Interventions
Panitumumab-IRDye800Drug
30 mg administered intravenously (IV)
89-Zirconium (Zr-89) PanitumumabDrug
0.8 to 1.2 mCi (29 to 45 Mbq) administered intravenously (IV)
Pinpoint IR IR9000 fluorescence imaging system (FIS)Device
Handheld fluorescence-imaging endoscope manufactured by Novadaq
SPY-PHI IR9000 fluorescence imaging system (FIS)Device
Handheld fluorescence-imaging endoscope manufactured by Novadaq
Explorer Air cameraDevice
Fluorescence camera manufactured by SurgVision
PDE-NEO II cameraDevice
Medical infrared camera manufactured by Hamamatsu Photonics KK
FIS-00 fluorescence imaging system (FIS)Device
Fluorescence-imaging system (FIS) manufactured by Hamamatsu Photonics KK
Da Vinci Firefly Imaging SystemDevice
Fluorescence-imaging endoscope, mounted or stand-alone, manufactured by Intuitive Surgical Inc
IGP-ELVIS-v4 Macroscopic Specimen ImagerDevice
Macroscopic specimen imager manufactured by LI-COR Biosciences
Vevo 3100 LAZR-XDevice
Photoacoustic ultrasound imaging system manufactured by VisualSonics
Pearl Triology Imaging SystemDevice
Near-infrared fluorescent and bioluminescent imaging system manufactured by LI-COR Biosciences
Odyssey CLx Imaging SystemDevice
Infrared fluorescent-imaging system manufactured by LI-COR Biosciences
Leica fluorescence microscopeDevice
Fluorescence microscope manufactured by Leica
Primary outcomes
What the sponsor says the trial is designed to measure.
- Detection of Tumor in Lymph Nodes by 18F-FDG and 89Zr-panitumumab LabelingTime frame: up to 5 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Stanford Cancer Institute Palo Alto
Palo Alto, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.